Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Dividends Calendar
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team
Pressemeddelelse

BioInvent International AB: BioStock: BioInvent's BI-1808 gains broad FDA support

BioInvent International

BioInvent has secured a win with the FDA granting Orphan Drug Designation to BI-1808 for T-cell lymphoma (TCL), a broad category covering multiple subtypes, including cutaneous T-cell lymphoma (CTCL). This news, paired with previously disclosed promising early data, arrives as the company anticipates further BI-1808 data by mid-2025, with additional readouts expected from its portfolio of six ongoing clinical programs throughout the year.

Read the article at biostock.se:

https://www.biostock.se/en/2025/03/bioinvents-bi-1808-gains-broad-fda-support/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.
  • Latest
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Dividends Calendar
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team